This study investigated VE-
statin/Egfl7 expression and its role and regulatory mechanism in
malignant glioma progression. Forty-five
paraffin-embedded
glioma (grade I-II: n=24; grade III-IV: n=21) were examined. VE-
statin/Egfl7
protein expression was detected via immunohistochemistry, and its correlation with pathological grade was evaluated. Three-dimensional cell culture was then performed to investigate the influence of VE-
statin/Egfl7 on the angiogenesis of umbilical vein endothelial cells. Microarray detection was used to molecularly profile VE-
statin/Egfl7 and relevant signaling pathways in
malignant glioma (U251 cells). Data showed that VE-
statin/Egfl7
protein was mainly expressed in the cytoplasm of
cancer and vascular endothelial cells and was significantly related to the degree of
malignancy (t=4.399, P<0.01). Additionally, VE-
statin/Egfl7 expression was low in certain gray-matter neurons but undetectable in glial cells. VE-
statin/Egfl7 gene silencing significantly inhibited angiogenesis in umbilical vein endothelial cells. The following microarray results were observed in VE-
statin/Egfl7-silenced U251 cells: 1) EGFR family members showed the highest differential expression, accounting for 5.54% of differentially expressed genes; 2) cell survival-related signaling pathways changed significantly; and 3) the
integrin ανβ3 signaling pathway was markedly altered. Thus,
malignant glioma cells and
glioma vascular endothelial cells highly express VE-
statin/Egfl7, which is significantly correlated with the degree of
malignancy. Moreover, VE-
statin/Egfl7 plays an important role in
glioma angiogenesis. Microarray results indicate that VE-
statin/Egfl7 may regulate EGFR and
integrins to influence the FAK activity of downstream factors, triggering the PI3K/Akt and Ras/MAPK cascades and subsequent
malignant glioma development.